Oragenics Stock Forum

$Oragenics (OGEN.US)$
Oragenics, Inc. Announces Closing of Public Offering

$Oragenics (OGEN.US)$
Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards
Oragenics (NYSE American: OGEN) has provided an update on its drug ONP-002, intended to treat concussion, and its non-compliance with NYSE American continued listing standards. Key developments include:
1. Demonstrated stability of ONP-002 across a wide temperature range.
2. Preparation for Phase 2 clinical trials, expected to start i...

$Oragenics (OGEN.US)$
Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range
Oragenics Inc. (NYSE American: OGEN) has announced that its lead candidate for treating concussion, ONP-002, demonstrates stability across a wide temperature range (-20°C to 104°C). This eliminates the need for cold storage, making it suitable for field use in sports and military operations. Key points:
1. ONP-002 is a new chemical entitydesigned for in...

$Oragenics (OGEN.US)$ Oragenics Inc: Onp-002 Showed No Cancer-Causing DNA Damage

$Oragenics (OGEN.US)$ As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032

$Oragenics (OGEN.US)$ EXCLUSIVE: Oragenics Tells Benzinga 'The Potential Addressable Market Opportunity for ONP-002 Includes an Estimated 69 Million Concussions Globally'

$Oragenics (OGEN.US)$ Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

$Oragenics (OGEN.US)$ Oragenics, Inc. (NYSE American: OGEN) Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing -  Oragenics, Inc., a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, announced its lead candidate for treating concussion successfully completed a study that indicates ONP-002 does not cause cardiotoxicity. ONP-002 is a new chemical entity (NCE) designed to target the brain through del...

$Oragenics (OGEN.US)$ On Thursday, Oragenics Inc. (NYSE:OGEN) announced that its lead candidate for treating concussion completed a study that indicates ONP-002 does not cause cardiotoxicity.